| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 25 May 2026 | 11 May 2026 |
| Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2026 ,inter alia, to consider and approve The Audited Financial Results for the quarter and financial year ended March 31, 2026 and recommendation of Final Dividend, if any. Outcome of the Board meeting held on 25th May, 2026 (As Per BSE Announcement Dated on:25.05.2026) The Board Meeting to be held on 18/05/2026 has been revised to 25/05/2026 The meeting of the Board of Directors of the Company has been rescheduled to May 25, 2026 (As per BSE Announcement dated on: 14.05.2026) Aarti Pharmalabs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. (As Per NSE Announcement Dated on : 25.05.2026) | ||
| Board Meeting | 9 Feb 2026 | 29 Jan 2026 |
| Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 inter alia to consider and approve 1. Unaudited Financial Results of the Company for the quarter and nine-months ended December 31 2025 after these results are reviewed by the Audit Committee of the Board. 2. Declaration of Interim Dividend if any on the equity share capital of the Company for the Financial Year 2025-26. AARTI PHARMALABS LIMITED has informed the Exchange about Board Meeting to be held on 09-Feb-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended December 31, 2025 and Dividend/Other business. Declaration of Interim Dividend at the rate of Rs. 1.5 per equity shares. (As Per BSE Announcement Dated on 09-02-2026) | ||
| Board Meeting | 9 Nov 2025 | 27 Oct 2025 |
| Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2025 inter alia to consider and approve Please find enclosed. Please find enclosed. Board at its Meeting held today, i.e., November 09, 2025 has inter-alia, approved the appointment of Senior Management Personnels of the Company: 1. Mr. Hemant Gundare as a Head Corporate - EHS (Environment, Health & Safety) and Senior Management Personnel of the Company w.e.f November 10, 2025 and 2. Mr. Shrihari S. Mane as a Chief Technology Officer (API) and Senior Management Personnel of the Company w.e.f November 10, 2025. (As Per BSE Announcement Dated on 09.11.2025) | ||
| Board Meeting | 12 Aug 2025 | 1 Aug 2025 |
| Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2025 inter alia to consider and approve The unaudited financial results (standalone and consolidated) for the quarter ended June 30 2025. Please find enclosed (As Per BSE Announcement Dated on:12.08.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
